Polymeric Anti‐Antibiotic Microparticles to Prevent Antibiotic Resistance Evolution (Small 21/2025)
Antibiotic Resistance In article number 2407549, Amir Sheikhi and co-workers report sevelamer (SEV), a Food and Drug Administration (FDA)-approved polymeric microparticle, as an adjuvant therapy to combat antimicrobial resistance. SEV captures off-target vancomycin and daptomycin in the gastrointestinal tract, preventing resistance enrichment in Enterococcus faecium. SEV therapy protects the last-resort antibiotics, which may address the global antimicrobial resistance crisis. Image created with BioRender.
Authors
- Roya Koshani (ORCID: https://orcid.org/0000-0001-9849-3963)
- Landon G. vom Steeg
- Robert J. Woods (ORCID: https://orcid.org/0000-0002-0679-9998)
- Naveen Narasimhalu
- Shang‐Lin Yeh (ORCID: https://orcid.org/0009-0003-7573-7760)
- Derek G. Sim
- Andrew F. Read (ORCID: https://orcid.org/0000-0001-7604-7903)
- Amir Sheikhi (ORCID: https://orcid.org/0000-0002-4495-6675)
- Zeming He
Institutions
- Dartmouth College (US)
- Pennsylvania State University (US)
- University of Michigan (US)
Publication Details
- Journal
- Small
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1002/smll.202570165
- Primary Topic
- Innovative Microfluidic and Catalytic Techniques Innovation
- Type
- article
- Field-Weighted Citation Impact
- 0.00